607 related articles for article (PubMed ID: 23946220)
21. Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection.
Tan DH; Raboud JM; Kaul R; Brunetta J; Kaushic C; Kovacs C; Lee E; Luetkehoelter J; Rachlis A; Smaill F; Smieja M; Walmsley SL
Clin Infect Dis; 2013 Aug; 57(3):448-57. PubMed ID: 23572481
[TBL] [Abstract][Full Text] [Related]
22. Subclinical Genital Herpes Shedding in HIV/Herpes Simplex Virus 2-Coinfected Women during Antiretroviral Therapy Is Associated with an Increase in HIV Tissue Reservoirs and Potentially Promotes HIV Evolution.
Stinn T; Kuntz S; Varon D; Huang ML; Selke S; Njikan S; Ford ES; Dragavon J; Coombs RW; Johnston C; Bull ME
J Virol; 2020 Dec; 95(1):. PubMed ID: 33028713
[TBL] [Abstract][Full Text] [Related]
23. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.
Ouedraogo A; Nagot N; Vergne L; Konate I; Weiss HA; Defer MC; Foulongne V; Sanon A; Andonaba JB; Segondy M; Mayaud P; Van de Perre P
AIDS; 2006 Nov; 20(18):2305-13. PubMed ID: 17117016
[TBL] [Abstract][Full Text] [Related]
24. A pilot study examining the safety and tolerability of valacyclovir in veterans with hepatitis C virus/herpes simplex virus type 2 coinfection.
Burton MJ; Penman A; Sunesara I; McGuire BM; Hook EW
Am J Med Sci; 2014 Dec; 348(6):455-9. PubMed ID: 25163019
[TBL] [Abstract][Full Text] [Related]
25. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573
[TBL] [Abstract][Full Text] [Related]
26. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.
Aurelius E; Franzen-Röhl E; Glimåker M; Akre O; Grillner L; Jorup-Rönström C; Studahl M;
Clin Infect Dis; 2012 May; 54(9):1304-13. PubMed ID: 22460966
[TBL] [Abstract][Full Text] [Related]
27. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
28. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
[TBL] [Abstract][Full Text] [Related]
29. Trial shows HSV-2 suppression can reduce HIV shedding.
IAVI Rep; 2006; 10(1):20. PubMed ID: 16628770
[No Abstract] [Full Text] [Related]
30. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
Vickerman P; Devine A; Foss AM; Delany-Moretlwe S; Mayaud P; Meyer-Rath G
Sex Transm Dis; 2011 May; 38(5):401-9. PubMed ID: 21317689
[TBL] [Abstract][Full Text] [Related]
31. Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.
Vanpouille C; Lisco A; Grivel JC; Bassit LC; Kauffman RC; Sanchez J; Schinazi RF; Lederman MM; Rodriguez B; Margolis L
Clin Infect Dis; 2015 Jun; 60(11):1708-14. PubMed ID: 25740794
[TBL] [Abstract][Full Text] [Related]
32. Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.
Tan DH; Raboud JM; Kaul R; Grinsztejn B; Cahn P; Walmsley SL
Trials; 2010 Nov; 11():113. PubMed ID: 21106086
[TBL] [Abstract][Full Text] [Related]
33. Health care seeking among men with genital ulcer disease in South Africa: correlates and relationship to human immunodeficiency virus-1 and herpes simplex virus type 2 detection and shedding.
Leichliter JS; Lewis DA; Sternberg M; Habel MA; Paz-Bailey G
Sex Transm Dis; 2011 Sep; 38(9):865-70. PubMed ID: 21844743
[TBL] [Abstract][Full Text] [Related]
34. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
35. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
36. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
37. Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.
Tan DH; Raboud JM; Szadkowski L; Yi TJ; Shannon B; Kaul R; Liles WC; Walmsley SL
AIDS Res Hum Retroviruses; 2015 Mar; 31(3):276-81. PubMed ID: 25399537
[TBL] [Abstract][Full Text] [Related]
38. Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey L; Wald A; Patel R; Sacks SL; Tyring SK; Warren T; Douglas JM; Paavonen J; Morrow RA; Beutner KR; Stratchounsky LS; Mertz G; Keene ON; Watson HA; Tait D; Vargas-Cortes M;
N Engl J Med; 2004 Jan; 350(1):11-20. PubMed ID: 14702423
[TBL] [Abstract][Full Text] [Related]
39. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
[TBL] [Abstract][Full Text] [Related]
40. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation.
Sheth PM; Sunderji S; Shin LY; Rebbapragada A; Huibner S; Kimani J; Macdonald KS; Ngugi E; Bwayo JJ; Moses S; Kovacs C; Loutfy M; Kaul R
J Infect Dis; 2008 May; 197(10):1394-401. PubMed ID: 18444797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
